Trecondi (treosulfan)
- Region
- 🇪🇺 EU
- Active substance
- treosulfan
- Company
- medac Gesellschaft für klinische Spezialpräparate mbH
- Status
- Authorised
- Therapeutic area
- Hematopoietic Stem Cell Transplantation
- EU approval
- Thu 20 Jun 2019
- Application
- EMEA/H/C/004751
- ATC
- L01AB02
- Official record
- www.ema.europa.eu
Indication
Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients and in paediatric patients older than one month with malignant and non-malignant diseases.
Regulatory milestones
No milestones recorded in the last year.
Follow Trecondi
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.